Pembrolizumab (Keytruda)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cancer
Conditions
Uterine Cancer
Trial Timeline
Nov 1, 2020 → Nov 1, 2023
NCT ID
NCT04262089About Pembrolizumab (Keytruda)
Pembrolizumab (Keytruda) is a phase 1 stage product being developed by Merck for Uterine Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04262089. Target conditions include Uterine Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05119296 | Phase 2 | Active |
| NCT04262089 | Phase 1 | Completed |
Competing Products
20 competing products in Uterine Cancer